ARTV (Artiva Biotherapeutics) Research & Development: $71.80 Mil (TTM As of Mar. 2026)


ARTV Artiva Biotherapeutics Inc ARTV
12 GF Score
Price $8.83
! 3 Warning Signs
View Full Analysis

What is Artiva Biotherapeutics Research & Development?

Artiva Biotherapeutics ARTV -5.16% 12 Research & Development is $71.80 Mil as of Mar. 2026. GuruFocus rates ARTV with a GF Score™ of 12/100. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Artiva Biotherapeutics's Research & Development for the three months ended in Mar. 2026 was $19.31 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $71.80 Mil.

Artiva Biotherapeutics  (NAS:ARTV) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Artiva Biotherapeutics Research & Development Related Terms

Artiva Biotherapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Artiva Biotherapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Artiva Biotherapeutics Research & Development Chart

Artiva Biotherapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 42.41 43.98 50.25 50.33 69.54

Artiva Biotherapeutics Quarterly Data
Dec19 Dec20 Mar21 Sep21 Dec21 Mar22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.05 17.86 17.63 16.99 19.31
ARTV
12GF Score
Artiva Biotherapeutics Inc ARTV
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Artiva Biotherapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $71.80 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $71.80 Mil mean?
Artiva Biotherapeutics (ARTV) has a Research & Development of $71.80 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Artiva Biotherapeutics and its competitors.
Is Artiva Biotherapeutics' Research & Development too high?
Artiva Biotherapeutics' current Research & Development is $71.80 Mil. Overall, Artiva Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Artiva Biotherapeutics' Research & Development compare to ENTA and VNDA?
Artiva Biotherapeutics' Research & Development of $71.80 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Artiva Biotherapeutics and its competitors. Artiva Biotherapeutics's current Research & Development is $71.80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artiva Biotherapeutics stock overvalued right now?
Artiva Biotherapeutics (ARTV) has a current Research & Development of $71.80 Mil. The current Research & Development is $71.80 Mil. Artiva Biotherapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Artiva Biotherapeutics (ARTV), the current Research & Development is $71.80 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Artiva Biotherapeutics Business Description

Address 5505 Morehouse Drive, Suite 100, San Diego, CA, USA, 92121
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
12GF Score

Get the complete analysis for ARTV

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.83
Price